aromasil has been researched along with Bone Cancer in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (36.36) | 29.6817 |
| 2010's | 12 (54.55) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Gulde, A; Hasanov, E; Krucke, GW; Krug, K | 1 |
| Chohan, B; Ferguson, A; Lewis, M; Nambi, R; Narang, I; Panthagani, AP | 1 |
| Cascinu, S; Depenni, R; Filieri, ME; Grizzi, G; Omarini, C; Piacentini, F | 1 |
| Chlebowski, RT; Lin, EM; Pan, K | 1 |
| Chavez Mac Gregor, M; Esteva, FJ; Griner, RL; Hess, KR; Hodge, S; Hortobagyi, GN; Koenig, KH; Moulder, SL; Patel, MM; Raghavendra, AS; Shroff, GS; Ueno, NT; Valero, V; Yam, C; Yeung, SJ | 1 |
| Cheng, Y; Cristofanilli, M; Cui, S; Feng, J; Gao, J; Geng, C; Gu, K; Hu, X; Jiang, Z; Li, W; Liu, T; Lu, X; Ning, Z; Ouyang, Q; Ouyang, T; Pan, Y; Sun, T; Sun, Y; Tong, Z; Wang, H; Wang, S; Wang, X; Yin, Y; Zhang, Q | 1 |
| Baselga, J; Burris, HA; Campone, M; Eakle, J; El-Hashimy, M; Geberth, M; Gnant, M; Hadji, P; Hart, LL; Hortobagyi, GN; Iwata, H; Lebwohl, D; Mukai, H; Noguchi, S; Piccart, M; Pritchard, KI; Rao, S; Rugo, HS; Sahmoud, T; Taran, T | 1 |
| Kuranishi, F; Ohno, T | 1 |
| Arena, FP; Baselga, J; Burris, HA; Cahana, A; Campone, M; Erdkamp, F; Feng, W; Gnant, M; Harb, WA; Hortobagyi, GN; Lebwohl, D; Melichar, B; Noguchi, S; Petrakova, K; Piccart, M; Pistilli, B; Pritchard, KI; Rugo, HS; Taran, T; Yardley, DA | 1 |
| Charalampous, P; Diamandi, M; Gkogkou, P; Ioannidis, G; Ioannou, R | 1 |
| Bondarenko, I; Brain, E; Campone, M; De Porre, P; Griffin, TW; Hayes, D; Johnston, S; Kheoh, T; Martin, J; Neven, P; O'Shaughnessy, J; Peng, W; Yu, MK | 1 |
| Berishaj, M; Bonafé, M; Bowman, RL; Bromberg, J; Ceccarelli, C; Chang, Q; Chen, J; Colameco, C; Cricca, M; Daly, L; DeMichele, A; Fabbri, N; Feldman, M; Gasparre, G; Healey, JH; Lyden, D; Mao, JJ; Nnoli, J; Perna, F; Rajasekhar, VK; Sansone, P; Santini, D; Shih, NN; Taffurelli, M; Vidone, M | 1 |
| Kawaoka, T; Kimura, Y; Kubo, H; Miyahara, M; Nagano, H; Nagashima, Y; Shimizu, R; Yamamoto, S | 1 |
| Beex, LV; Bogaerts, J; Cameron, DA; Cufer, T; Dirix, LY; Nooij, M; Paridaens, RJ; Piccart, MJ; Therasse, P | 1 |
| Bachelot, T; Baselga, J; Beck, JT; Burris, HA; Campone, M; Deleu, I; Gnant, M; Hortobagyi, GN; Ito, Y; Lebrun, F; Lebwohl, D; Mukhopadhyay, P; Noguchi, S; Perez, A; Piccart, M; Pritchard, KI; Rugo, HS; Sahmoud, T; Vittori, L; Xu, Z; Yardley, D | 1 |
| Suda, T | 1 |
| Baelde, HJ; Bovée, JV; Cleton-Jansen, AM; Hogendoorn, PC; Karperien, M; van Beerendonk, HM | 1 |
| Giordano, SH; Hortobagyi, GN | 1 |
| Suzuki, M | 1 |
| Bundred, NJ | 1 |
| Beresford, MJ; Chin, YS; Makris, A; Ravichandran, D | 1 |
| Amaddeo, P; Barbaglio, A; Faldi, F; Fontana, S; Ghilardi, R; Pericotti, S | 1 |
7 trial(s) available for aromasil and Bone Cancer
| Article | Year |
|---|---|
Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Drug Therapy, Combination; Everolimus; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Obesity; Overweight; Postmenopause; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate | 2019 |
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aminopyridines; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Breast Neoplasms; Double-Blind Method; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Salvage Therapy; Survival Rate; Treatment Outcome | 2019 |
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.
Topics: Aged; Alkaline Phosphatase; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Bone Resorption; Breast Neoplasms; Collagen Type I; Confounding Factors, Epidemiologic; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Middle Aged; Odds Ratio; Osteogenesis; Postmenopause; Procollagen; Proportional Hazards Models; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases; Treatment Failure; Treatment Outcome | 2013 |
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Everolimus; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Treatment Outcome | 2013 |
Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Middle Aged; Postmenopause; Proportional Hazards Models; Receptors, Estrogen; Treatment Outcome | 2016 |
Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Estrogen Antagonists; Female; Humans; Lymphatic Metastasis; Middle Aged; Postmenopause; Soft Tissue Neoplasms; Tamoxifen; Treatment Outcome | 2008 |
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; ErbB Receptors; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Postmenopause; Recurrence; Sirolimus; Stomatitis; TOR Serine-Threonine Kinases | 2012 |
15 other study(ies) available for aromasil and Bone Cancer
| Article | Year |
|---|---|
Everolimus-induced pneumonitis: A diagnostic challenge.
Topics: Androstadienes; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Ductal, Breast; Computed Tomography Angiography; Cough; Diagnosis, Differential; Dyspnea; Everolimus; Female; Glucocorticoids; Humans; Lung Neoplasms; Methylprednisolone; Middle Aged; Pneumonia; Pneumonia, Bacterial; Pulmonary Embolism; Pulse Therapy, Drug; Radiography, Thoracic; Tomography, X-Ray Computed | 2020 |
COVID-19-induced toxic epidermal necrolysis.
Topics: Adrenal Cortex Hormones; Androstadienes; Aromatase Inhibitors; Body Surface Area; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; COVID-19; Dexamethasone; Emollients; Female; Hospitalization; Humans; Liver Neoplasms; Middle Aged; Palliative Care; SARS-CoV-2; Stevens-Johnson Syndrome | 2021 |
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid.
Topics: Androstadienes; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cone-Beam Computed Tomography; Diagnosis, Differential; Everolimus; Female; Humans; Jaw Diseases; Mastectomy; Middle Aged; Osteonecrosis | 2017 |
Emerging combination endocrine therapies for advanced breast cancer.
Topics: Adult; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Everolimus; Female; Humans; Lung Neoplasms; Receptor, ErbB-2; Receptors, Estrogen | 2018 |
Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Bone Neoplasms; Breast Neoplasms; Cancer Vaccines; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Diphosphonates; Epirubicin; Female; Fixatives; Fluorouracil; Formaldehyde; Humans; Imidazoles; Magnetic Resonance Imaging; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prognosis; Radiotherapy Dosage; Tomography, Emission-Computed, Single-Photon; Triazoles; Zoledronic Acid | 2013 |
Radiation-recall dermatitis with the everolimus/exemestane combination ten years after adjuvant whole-breast radiotherapy.
Topics: Androstadienes; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Drug Therapy, Combination; Everolimus; Female; Humans; Liver Neoplasms; Middle Aged; Neoplasms, Second Primary; Radiodermatitis; Radiotherapy, Adjuvant; Sirolimus | 2014 |
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Line, Tumor; Cell Self Renewal; Drug Resistance, Neoplasm; Estradiol; Female; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; In Vitro Techniques; Interleukin-6; Letrozole; Leuprolide; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Nitriles; Oxidative Phosphorylation; Peptides; Real-Time Polymerase Chain Reaction; Receptor, Notch3; Receptors, Estrogen; Receptors, Notch; Signal Transduction; Tamoxifen; Triazoles | 2016 |
[A Case of Recurrent Breast Cancer with Bone Metastasis Successfully Treated with Everolimus and Exemestane Therapy].
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Everolimus; Female; Humans; Middle Aged; Recurrence; Treatment Outcome | 2017 |
[Effective reduction of elevated tumor markers by exemestane--a 12-year follow-up of a case of bone metastatic breast cancer].
Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Carcinoembryonic Antigen; Drug Administration Schedule; Female; Floxuridine; Humans; Medroxyprogesterone Acetate; Mucin-1; Radionuclide Imaging | 2005 |
Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma.
Topics: Adult; Aged; Androstadienes; Androstenedione; Aromatase; Aromatase Inhibitors; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Chondrosarcoma; Dose-Response Relationship, Drug; Estrogen Antagonists; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Metastasis; Receptors, Estrogen; RNA, Messenger; Signal Transduction | 2005 |
Leuprolide acetate plus aromatase inhibition for male breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Humans; Letrozole; Leuprolide; Lung Neoplasms; Lymphatic Metastasis; Male; Mastectomy, Modified Radical; Middle Aged; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Triazoles | 2006 |
[A patient with advanced breast cancer refractory to chemotherapy accompanied by carcinomatous pleurisy and multiple bone metastasis that responded to combination therapy with high-dose toremifene and docetaxel].
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Paclitaxel; Pleural Effusion, Malignant; Pleural Neoplasms; Quality of Life; Remission Induction; Taxoids; Toremifene | 2007 |
Optimising bone health in survivors of breast cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Density; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Female; Humans; Postmenopause; Survivors; Tamoxifen | 2007 |
Exemestane after non-steroidal aromatase inhibitors for post-menopausal women with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Postmenopause; Retrospective Studies; Soft Tissue Neoplasms | 2007 |
Male breast cancer with mandibular metastasis. A case report.
Topics: Aged; Androstadienes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Cortisone; Cyclophosphamide; Diphosphonates; Docetaxel; Fatal Outcome; Fluorouracil; Furosemide; Humans; Imidazoles; Liver Neoplasms; Male; Mandibular Neoplasms; Mastectomy, Modified Radical; Methotrexate; Omeprazole; Osteolysis; Phenobarbital; Taxoids; Toremifene; Vinblastine; Vinorelbine; Zoledronic Acid | 2007 |